Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$2.06 +5.1%	$1.37	$0.40 ▼ $2.25	$33.28M	0.19	310,645 shs	187,583 shs
CMMB Chemomab Therapeutics	$1.20 +1.7%	$1.28	$0.87 ▼ $2.55	$22.25M	0.48	218,970 shs	86,693 shs
KLTO Klotho Neurosciences	$1.44 +20.0%	$0.50	$0.11 ▼ $5.11	$38.99M	0.18	30.76 million shs	9.23 million shs
LPCN Lipocine	$3.20 +1.9%	$3.29	$2.68 ▼ $8.71	$16.80M	1.34	33,087 shs	2,507 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+6.52%	+0.51%	+70.43%	+178.01%	+174.89%
CMMB Chemomab Therapeutics	-1.67%	-4.07%	-13.55%	+3.51%	+26.88%
KLTO Klotho Neurosciences	-22.08%	-27.71%	+524.02%	+361.36%	+119,999,900.00%
LPCN Lipocine	-4.85%	+2.61%	-12.29%	-11.80%	-65.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVC ABVC BioPharma	0.0978 of 5 stars	0.0	3.0	0.0	0.0	0.0	0.8	0.0
CMMB Chemomab Therapeutics	3.153 of 5 stars	3.5	5.0	0.0	0.0	0.0	1.7	0.6
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	1.6567 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	0.00	N/A	N/A	N/A
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	608.33% Upside
KLTO Klotho Neurosciences	0.00	N/A	N/A	N/A
LPCN Lipocine	3.00	Buy	$9.00	181.25% Upside

Current Analyst Ratings Breakdown

Latest KLTO, ABVC, CMMB, and LPCN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/29/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00
5/16/2025	CMMB Chemomab Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$11.00 ➝ $10.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	68.59	N/A	N/A	$0.06 per share	34.33
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A
LPCN Lipocine	$11.20M	1.53	N/A	N/A	$3.93 per share	0.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$4.90M	-$0.13	N/A	∞	N/A	-963.46%	-29.62%	-14.08%	8/13/2025 (Estimated)
CMMB Chemomab Therapeutics	-$13.94M	-$0.76	N/A	N/A	N/A	N/A	-106.70%	-82.18%	8/20/2025 (Estimated)
KLTO Klotho Neurosciences	-$6.15M	-$0.36	N/A	∞	N/A	N/A	-1,779.01%	-275.01%	N/A
LPCN Lipocine	$10K	-$1.02	N/A	∞	N/A	N/A	-26.68%	-24.77%	8/6/2025 (Estimated)

Latest KLTO, ABVC, CMMB, and LPCN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.14	+$0.06	-$0.14	N/A	N/A
5/15/2025	Q1 2025	KLTO Klotho Neurosciences	N/A	-$0.08	N/A	-$0.08	N/A	N/A
5/8/2025	Q4 2024	LPCN Lipocine	-$0.35	-$0.35	N/A	-$0.35	$0.35 million	$0.09 million
4/30/2025	Q4 2024	ABVC ABVC BioPharma	N/A	-$0.06	N/A	-$0.06	N/A	N/A
4/15/2025	Q4 2024	ABVC ABVC BioPharma	N/A	$0.04	N/A	$0.04	N/A	N/A
3/31/2025	Q4 2024	KLTO Klotho Neurosciences	N/A	-$0.07	N/A	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.22	0.22
CMMB Chemomab Therapeutics	N/A	5.33	5.33
KLTO Klotho Neurosciences	N/A	0.29	0.29
LPCN Lipocine	N/A	15.64	15.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
CMMB Chemomab Therapeutics	46.05%
KLTO Klotho Neurosciences	20.07%
LPCN Lipocine	9.11%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	17.10%
CMMB Chemomab Therapeutics	11.91%
KLTO Klotho Neurosciences	26.70%
LPCN Lipocine	6.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	16.98 million	14.08 million	Not Optionable
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
KLTO Klotho Neurosciences	N/A	32.49 million	23.82 million	N/A
LPCN Lipocine	10	5.35 million	5.01 million	No Data

KLTO, ABVC, CMMB, and LPCN Headlines

Recent News About These Companies

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

June 23 at 8:00 AM | prnewswire.com

Le partenaire de Lipocine dépose une demande d’approbation au Canada pour un médicament TRT oral

June 9, 2025 | fr.investing.com

Lipocine annonce le dépôt d'une demande d'autorisation de mise sur le marché pour TLANDO au Canada

June 9, 2025 | zonebourse.com

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

June 9, 2025 | prnewswire.com

Le LPCN 1148 de Lipocine mis en avant dans l'édition de juin 2025 de Hepatology

May 23, 2025 | zonebourse.com

Lipocine’s LPCN 1148 Gains Fast Track Designation

May 22, 2025 | tipranks.com

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 22, 2025 | prnewswire.com

Lipocine to Present at A.G.P. Healthcare Showcase

May 14, 2025 | tipranks.com

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2025 | prnewswire.com

Lipocine Reports Q1 2025 Financial Results

May 8, 2025 | tipranks.com

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 8, 2025 | prnewswire.com

Lipocine inks license and supply agreement for TLANDO in Brazil

May 7, 2025 | msn.com

Lipocine s’associe à Aché pour commercialiser TLANDO au Brésil

May 7, 2025 | fr.investing.com

Lipocine Inc. annonce un accord de licence et d'approvisionnement pour Tlando® au Brésil

May 7, 2025 | zonebourse.com

Lipocine Partners with Aché for TLANDO® in Brazil

May 6, 2025 | tipranks.com

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

May 6, 2025 | prnewswire.com

L’action LPCN atteint son plus bas niveau sur 52 semaines à 2,91$

April 7, 2025 | fr.investing.com

Lipocine Inc. Reports 2024 Financial Turnaround

April 4, 2025 | tipranks.com

Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression

March 27, 2025 | finance.yahoo.com

Lipocine initiates Phase 3 trial for LPCN 1154

March 27, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLTO, ABVC, CMMB, and LPCN Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$2.06 +0.10 (+5.10%)

Closing price 04:00 PM Eastern

Extended Trading

$2.09 +0.03 (+1.65%)

As of 07:47 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Chemomab Therapeutics NASDAQ:CMMB

$1.20 +0.02 (+1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$1.20 0.00 (0.00%)

As of 06:06 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Klotho Neurosciences NASDAQ:KLTO

$1.44 +0.24 (+20.00%)

As of 04:00 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Lipocine NASDAQ:LPCN

$3.20 +0.06 (+1.91%)

Closing price 03:53 PM Eastern

Extended Trading

$3.19 -0.01 (-0.28%)

As of 04:46 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time